TELEFLEX INCTFX

時価総額

$48.7億

PER

医療機器メーカーの大手。UroLiftなどの尿路治療製品、血管介入・血管アクセス製品を展開。2017年にNeoTractとVascular Solutionsを買収、2025年2月にBIOTRONIKのVI事業を初期対価€760百万で買収合意。米国・欧州・アジアで展開。

概要財務

サマリーテーブルに戻る

	2010年 12月31日	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income	202	325	-189	152	189	246	238	153	201	461	335	485	363	356	70
Loss (income) from discontinued operations	77	203	-7	-0	-3	9	0	-3	4	-1	-0	0	0	-1	-0
Depreciation	48	42	36	42	50	46	54	56	60	64	69	72	67	68	77
Amortization of Intangible Assets	44	44	44	51	61	62	63	99	150	150	159	166	164	174	198
Amortization of Debt Issuance Costs and Discounts	-	14	14	15	16	17	10	5	5	4	4	4	4	3	3
Loss on extinguishment of debt	-47	-15	-	-1	-	-10	-19	-6	-	-9	-	-13	-0	-	-
Pension settlement charge	-	-	-	-	-	-	-	-	-	-	-	-	-	-45	-133
Inventory, Fair Value Step Up	-	-	-	-	-	-	-	10	-	-	2	4	-	2	2
Changes in contingent consideration	-	-	-	-	-	-	-	-	-	54	-38	8	2	-27	10
Asset impairments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8
Stock-based compensation	10	4	9	12	12	14	17	19	22	27	21	23	27	31	31
Gain on sale of assets and business	-	-1	0	-	-	0	4	-	1	6	-	91	7	4	-
Goodwill, Impairment Loss	-	-	332	-	-	-	-	-	-	-	-	-	-	-	240
Deferred income taxes, net	1	-13	-39	-9	-14	-54	-29	-42	-6	-169	-33	-110	-13	-13	-130
Payments for contingent consideration	-	-	-	-13	-7	-5	-6	4	53	-26	-80	0	3	0	-
Interest benefit on swaps designated as net investment hedges	-	-	-	-	-	-	-	-	-	19	19	19	21	19	17
Other	-	-	-3	-9	-9	-21	-13	-18	-19	-6	-27	-36	-3	6	16
Accounts receivable	56	43	3	1	-9	-0	11	11	23	60	-45	1	38	16	28
Inventories	4	33	2	9	16	8	-6	22	37	53	5	11	111	41	-2
Prepaid expenses and other assets	8	8	-10	6	-1	3	4	-1	10	31	4	28	-13	11	-43
Accounts payable, accrued expenses and other liabilities	-1	-0	-1	-1	10	-0	15	39	62	36	1	94	-25	-31	10
Income taxes	-	-29	-20	-7	-15	8	11	126	-36	-7	-13	73	-79	-12	-28
Net cash provided by operating activities from continuing operations	207	103	194	230	290	303	411	426	435	437	437	652	343	512	638
Expenditures for property, plant and equipment	34	45	65	64	68	61	53	71	81	103	91	72	79	91	126
Payments for businesses and intangibles acquired, net of cash acquired	0	31	387	309	46	94	14	1,768	121	3	768	5	198	604	0
Proceeds from Divestiture of Businesses	182	376	67	-	5	0	10	6	4	14	1	225	12	15	-
Proceeds from Hedge, Investing Activities	-	-	-	-	-	-	-	-	2	18	19	19	21	63	27
Proceeds from sales of investments	-	-	-	-	-	-	-	-	-	-	-	7	7	7	7
Purchase of investments	-	-	-	-	-	-	-	-	-	-	-	18	22	11	7
Net cash (used in) provided by investing activities from continuing operations	148	300	-386	-373	-108	-155	-57	-1,833	-196	-73	-	-	-259	-621	-99
Proceeds from new borrowings	490	515	-	680	250	288	672	2,464	35	275	1,514	400	744	646	130
Reduction in borrowings	717	456	-	375	480	304	715	1,240	129	529	939	1,035	885	545	292
Debt extinguishment, issuance and amendment fees	65	19	-	6	4	9	9	27	0	12	8	10	5	-	-
Repurchase of common stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	200
Net proceeds from share based compensation plans and the related tax impacts	-	-	-	-	-	-	-	-	-	-	-	-	-	5	3
Payments for contingent consideration	-	-	-	17	-	8	7	0	73	112	67	31	4	4	0
Dividends paid	54	55	56	56	56	57	59	61	62	63	63	64	64	64	64
Net cash (used in) provided by financing activities from continuing operations	-	-	-	-	-	-	-	-	-	-	455	-716	-218	39	-422
Net cash used in operating activities	7	-9	-8	-3	-4	-3	-2	-6	2	2	-1	-1	-1	-1	-3
Net cash provided by investing activities	-1	-2	-2	-	-	-	-	-	-	-	-	-	1	-	-
Net cash (used in) provided by discontinued operations	6	-11	-10	-3	-4	-3	-2	-6	2	2	-1	-1	1	-1	-3
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents	-	-	-	-	-	-	-	-	-	-3	21	-23	-20	3	-10
Net increase (decrease) in cash, cash equivalents and restricted cash equivalents	-	-	-	-	-	-	-	-	-	-56	75	69	-153	-69	105